As the Chair and Founder of the House Affordable Prescription Drug Task Force, I am committed to bringing more oversight and transparency to drug pricing and supporting legislative and administrative solutions so that more families can afford the medicine they need.
I am committed to bringing more oversight and transparency to drug pricing and supporting legislative and administrative solutions so that more families can afford the medicine they need.
Occurrences
Mr. Doggett was listed as a cosponsor of H.R. 10094, the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026, whose full title states: "To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes."
this legislation delivers meaningful protections to ensure all Americans are charged fair and reasonable prices when taxpayers contribute research and development funding
Evidence
unverified · Source version 1372 · locator unknown
House Roll Call 420 on H.R. 5376 passed, 220-207. The vote list records Doggett, Democratic, Texas: Yea.
unverified · Source version 26321 · locator unknown
CMS says the first 10 negotiated Medicare Part D prices go into effect January 1, 2026, with projected enrollee savings of $1.5 billion.
unverified · Source version 33418 · locator unknown
CMS announced 15 additional Medicare Part D drugs for direct price negotiation, said negotiations would occur in 2025, and said any negotiated prices would take effect in 2027. The same release said the first-cycle negotiated prices would take effect on January 1, 2026 and were expected to produce additional beneficiary savings.
unverified · Source version 1372 · locator unknown
Doggett voted Yea on H.R. 5376, the reconciliation vehicle that became the Inflation Reduction Act and created Medicare drug-price negotiation authority.
unverified · Source version 60621 · locator unknown
For any selected drugs for which CMS and participating drug companies have agreed upon negotiated prices under the Medicare Drug Price Negotiation Program, which the statute refers to as maximum fair prices (MFPs) the file also contains the single negotiated price for a 30-day equivalent supply of each selected drug, NDC-9 per unit price, and NDC-11 per package price, as well as other important information regarding updates to the NDCs and MFPs.
unverified · Source version 60621 · locator unknown
CMS announced on March 13, 2026 that the drug companies that manufacture all 15 drugs payable under Medicare Part B and/or covered under Medicare Part D selected for the third cycle of negotiation have chosen to participate in the Negotiation Program.
verified · Source version 60623 · locator 511
Ms. Hoyle of Oregon (for herself, Mr. Doggett, Ms. Stansbury, Mr. Takano, Ms. Norton, Ms. Tlaib, Ms. Jayapal, and Mr. Casar) introduced the following bill; which was referred to the Committee on Energy and Commerce
verified · Source version 60623 · locator 5479
The Secretary shall make all reports under paragraph (1) publicly available.
unverified · Source version 60625 · locator unknown
The Plaintiffs challenge the constitutionality of the Drug Pricing Program created by the Inflation Reduction Act of 2022. They claim violations of the nondelegation doctrine, the Eighth Amendment’s Excessive Fines Clause, and the Fifth Amendment’s Due Process Clause. The district court granted the Government’s motion for summary judgment. We AFFIRM.
unverified · Source version 60627 · locator unknown
Upon consideration of the parties’ submissions, the relevant legal authority, and the entire record, the Court shall DENY Merck’s [23] Motion for Summary Judgment in full and GRANT the Government’s [24] Cross-Motion for Summary Judgment in full.
Assessments
Doggett materially advanced the drug-pricing agenda by voting for the Inflation Reduction Act, which created Medicare drug-price negotiation authority, and CMS later implemented negotiated prices and additional negotiation rounds. That is concrete legislative and administrative follow-through on affordability and oversight, but the pledge is broader than these steps and the overall transparency/oversight goal is not fully exhausted, so this is partial rather than complete delivery.
Doggett materially supported federal drug-pricing reforms by voting for H.R. 5376, the Inflation Reduction Act, which authorized Medicare drug-price negotiation and related affordability measures. CMS implementation of the first negotiated Medicare Part D prices taking effect on January 1, 2026 provides a concrete same-term affordability and transparency outcome while Doggett remains in federal office. However, the promise was broad, covering more oversight, transparency, and wider affordability for families generally, and the evidence shows meaningful progress rather than full realization across drug pricing.